Welcome to our dedicated page for Definitive Healthcare news (Ticker: DH), a resource for investors and traders seeking the latest updates and insights on Definitive Healthcare stock.
About Definitive Healthcare Corp. (DH)
Definitive Healthcare Corp. (Nasdaq: DH) is a leading provider of healthcare commercial intelligence, delivering actionable data and insights to organizations across the healthcare ecosystem. The company's mission is to transform data, analytics, and expertise into meaningful intelligence that enables its clients to uncover opportunities, optimize strategies, and drive growth. By leveraging a robust SaaS-based platform, Definitive Healthcare empowers clients to navigate the complexities of the healthcare market with precision and confidence.
Comprehensive Data and Analytics Platform
At the core of Definitive Healthcare's offerings is its proprietary platform, which aggregates and analyzes data on over 8,100 hospitals, 7,300 ambulatory surgery centers, 11,000 imaging centers, 38,000 long-term care facilities, 1,200 accountable care organizations (ACOs) and health information exchanges (HIEs), 197,000 physician groups, 1.3 million physicians, and 750 Canadian hospitals. This extensive dataset provides clients with unparalleled visibility into the healthcare provider landscape, enabling them to make informed decisions in areas such as market segmentation, sales execution, and product development.
Key Solutions and Products
- Monocl ExpertInsight: A comprehensive tool that delivers data on more than 15 million medical experts globally, helping pharmaceutical and medtech companies enhance Key Opinion Leader (KOL) engagement and clinical collaboration.
- Population Intelligence: Combines clinical and consumer data to enable precision marketing, allowing businesses to identify and target specific audience segments effectively.
- Carevoyance: A solution tailored for medtech sales teams, providing deep insights into provider segmentation, territory alignment, and sales tracking to streamline workflows and accelerate device adoption.
- Market Forecast: A predictive analytics tool that offers three, five, and ten-year market trend projections, helping healthcare organizations plan strategically for future demand and growth opportunities.
- DH View Suite: A mobile-enabled platform that equips sales and marketing teams with instant access to critical intelligence on healthcare professionals and organizations, enhancing productivity and client engagement.
- Monocl Conferences: A specialized solution for life sciences organizations to optimize conference planning and participation, providing insights into key presentations, trending topics, and expert engagement opportunities.
Market Position and Competitive Landscape
Operating within the rapidly evolving healthcare data analytics industry, Definitive Healthcare stands out for its depth of data, innovative solutions, and focus on healthcare-specific use cases. Its competitors include companies like IQVIA and Truveta, but Definitive Healthcare differentiates itself through its tailored SaaS offerings and the integration of predictive analytics with real-time data visualization. The company's solutions address critical challenges faced by healthcare organizations, such as identifying high-growth markets, optimizing sales territories, and enhancing patient engagement strategies.
Revenue Model and Geographic Focus
Definitive Healthcare generates the majority of its revenue through subscription-based services, offering scalable solutions that cater to organizations of all sizes. While its primary market is the United States, the company also provides data on international healthcare providers, particularly in Canada, further broadening its client base and market reach.
Challenges and Opportunities
As a data-centric organization, Definitive Healthcare faces challenges such as ensuring the accuracy and comprehensiveness of its datasets, navigating complex regulatory environments, and mitigating cybersecurity risks. However, its investments in proprietary data science, AI-driven analytics, and user-friendly interfaces position it well to address these challenges and capitalize on growing demand for healthcare intelligence solutions.
Conclusion
Definitive Healthcare Corp. is a pivotal player in the healthcare commercial intelligence space, enabling organizations to unlock new opportunities and optimize their operations through data-driven insights. With its diverse product portfolio, deep industry expertise, and commitment to innovation, Definitive Healthcare continues to shape the future of the healthcare market, providing clients with the tools they need to succeed in an increasingly competitive landscape.
Definitive Healthcare (Nasdaq: DH) has expanded its Population Intelligence platform to serve a wider range of industries selling into healthcare. The platform now supports businesses in sectors like advertising, marketing, telehealth, staffing, and medical supply to enhance marketing campaigns and digital advertising performance.
Population Intelligence combines clinical and consumer data on over 250 million unique consumers aged 18+, offering 300+ clinical propensity, social determinants of health, and media channel models. This allows businesses to create precise audience segments and launch targeted marketing campaigns, driving efficient consumer activation.
The platform enables teams to segment markets, build campaign audiences, and activate audiences for digital advertising. It integrates with organizations' internal systems while keeping first-party data secure, promoting compliance with data privacy standards.
Definitive Healthcare Corp. (Nasdaq: DH) reported financial results for Q2 2024. Revenue grew 5% year-over-year to $63.7 million. The company incurred a net loss of $306.2 million, primarily due to goodwill impairment charges of $363.6 million. However, Adjusted EBITDA increased 21% to $20.9 million, representing 33% of revenue.
Key highlights include:
- Adjusted Net Income: $14.2 million
- Cash Flow from Operations: $14.0 million
- Unlevered Free Cash Flow: $21.5 million
- Enterprise customers grew by 32 (6% YoY) to 537
For Q3 2024, DH expects revenue between $61.0-$62.5 million and Adjusted EBITDA of $17.5-$19.0 million. Full-year 2024 guidance projects revenue of $247-$251 million and Adjusted EBITDA of $74-$77 million.
Definitive Healthcare Corp. (Nasdaq: DH), a leader in healthcare commercial intelligence, has announced the timing for its second quarter 2024 financial results conference call and webcast. The company will report its financial results for the quarter ended June 30, 2024, on Monday, August 5, 2024, after market close.
A conference call and webcast will be held at 5:00 PM (ET) / 2:00 PM (PT) to discuss the results. Investors can access the live audio webcast on the company's Investor Relations website. A live dial-in will also be available. Following the call, a replay will be accessible through September 4, 2024.
Definitive Healthcare (Nasdaq: DH) has launched a redesigned mobile app for its View Suite platform, aimed at enhancing accessibility to healthcare commercial intelligence. Announced on July 09, 2024, the new DH View Suite mobile app provides sales and marketing teams with instant access to essential data, optimizing their productivity in the field. The app offers detailed profiles of healthcare professionals and organizations, including metrics on clinical performance, finances, and more. Available for download on Apple and Android devices at no additional cost to existing customers, the app ensures that users are always prepared for client meetings and industry events.
On June 25, 2024, Definitive Healthcare (Nasdaq: DH) announced the granting of inducement awards to its new CEO, Kevin Coop. The awards include 1,137,038 performance-based restricted stock units (PSUs) and 1,170,047 time-based restricted stock units (RSUs), effective June 24, 2024. These grants are in accordance with Nasdaq Listing Rule 5635(c)(4) and are a part of the company's 2023 Inducement Plan.
The RSUs will vest in stages, with one-fourth vesting on July 1, 2025, and the rest in 12 equal quarterly installments. The PSUs are divided into four tranches, tied to specific stock price hurdles and performance periods, with vesting subject to the Human Capital Management and Compensation Committee's certification and Mr. Coop's continued service.
Definitive Healthcare (Nasdaq: DH) has been awarded the 2024 Databricks Healthcare and Life Sciences Partner of the Year. This accolade highlights their successful collaboration with Databricks in offering innovative data and AI solutions to the healthcare and life sciences sector.
Leveraging the Databricks Marketplace, Definitive Healthcare provides access to extensive datasets, including prescription claims, behavioral health data, and affiliations intelligence. This aids organizations in understanding patient journeys, prioritizing opportunities, and engaging key medical experts for better healthcare outcomes.
Casey Eastlack, AVP at Definitive Healthcare, expressed pride in the recognition, emphasizing the shared mission to deliver deeper and faster healthcare insights for improved decision-making and innovation. Michael Sanky of Databricks praised the partnership's impact on advancing outcomes for customers in the sector.
Definitive Healthcare (Nasdaq: DH) published its 2023 Sustainability Report, showcasing its achievements in environmental, social, and governance (ESG) practices. Highlights include the retention of an ESG consultant to measure greenhouse gas emissions, and the closure of its least energy-efficient office. On the social front, the company improved diversity at the executive level, contributed 1,940 volunteer hours, and raised over $300,000 in charitable donations. In governance, Definitive Healthcare completed a SOC2 assessment and enhanced its cybersecurity and data privacy framework.
Definitive Healthcare, a leader in healthcare commercial intelligence, announced that Founder, Interim CEO, and Executive Chairman, Jason Krantz, will present at the Stifel 2024 Cross Sector Insight Conference. The presentation is scheduled for June 4, 2024, at 9:10 a.m. ET. A live webcast will be available on the Definitive Healthcare investor relations website, with a replay accessible for a time. The announcement highlights the company's active role in industry events and its ongoing efforts to engage with investors and stakeholders.
Definitive Healthcare (Nasdaq: DH) announced the appointment of Kevin Coop as CEO, effective June 24, 2024. Coop replaces Jason Krantz, who served as Interim CEO and will remain as Executive Chairman. Coop brings over 30 years of experience in operations, product, and revenue growth, including leadership roles at DailyPay, Dun & Bradstreet, Black Knight, and Verisk Analytics. The company aims to leverage Coop's expertise to capitalize on the $10 billion healthcare commercial intelligence market, enhancing growth, innovation, and operational efficiency.
On May 14, 2024, Definitive Healthcare announced that its Founder, Interim CEO, and Executive Chairman, Jason Krantz, will present at the 52nd Annual J.P. Morgan Global Technology, Media and Communications Conference. The presentation is scheduled for May 21, 2024, at 10:10 a.m. Eastern Time. A live webcast of the event will be available on the company's investor relations website, with a replay accessible for a period.
FAQ
What is the current stock price of Definitive Healthcare (DH)?
What is the market cap of Definitive Healthcare (DH)?
What does Definitive Healthcare Corp. do?
What industries does Definitive Healthcare serve?
How does Definitive Healthcare generate revenue?
What are some of Definitive Healthcare's key products?
What makes Definitive Healthcare unique in its industry?
Who are Definitive Healthcare's competitors?
What challenges does Definitive Healthcare face?
What geographic regions does Definitive Healthcare cover?
What is Monocl ExpertInsight?
How does Population Intelligence benefit businesses?
